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Abstract
Pro-inflammatory cytokines and bone morphogenetic
proteins are generally studied separately and considered
to be elements of different worlds, immunology and
developmental biology. Varas and colleagues report
that these factors show cross-talk in rheumatoid
arthritis synoviocytes. They show that pro-inflammatory
cytokines not only stimulate the production of bone
morphogenetic proteins but that these endogenously
produced bone morphogenetic proteins interfere
with the effects of pro-inflammatory cytokines on
synoviocytes.
Editorial
Varas and colleagues report in this volume that pro-
inflammatory cytokines stimulate the production of bone
morphogenetic proteins and that endogenously produced
bone morphogenetic proteins interfere with the effects of
pro-inflammatory cytokines on synoviocytes [1]. Both
tumor necrosis factor (TNF)-α and interleukin (IL)-17 are
hallmark cytokines with a dominant function in the im-
munology of rheumatoid arthritis (RA) [2, 3]. Targeting
TNF-α is the prevailing biological therapy to treat RA pa-
tients, while targeting IL-17 could be a valuable addition
for the management of a subgroup of patients [4]. Both
TNF-α and IL-17 are factors that exemplify the dominant
role of aberrant immune function in RA.
Bone morphogenetic proteins (BMPs), alternatively
called body morphogenetic proteins, are ligands of the
transforming growth factor (TGF)-β superfamily, which
are central in embryology and developmental biology
[5]. Ligands of this family determine cell and tissue fate
from early embryogenesis to the formation of complex
organs such heart, kidney and others [6, 7].
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A few studies have addressed interactions between
TNF-α/IL-17 and the BMPs. Expression of BMPs and
regulation of their expression by pro-inflammatory cyto-
kines has been shown in RA synovial tissue [8]. The
expression of BMP-2 is enhanced by TNF-α in osteoarth-
ritic chondrocytes and pro-inflammatory T-cell cytokines
have been suggested to play a role in the differentiation of
mesenchymal stromal cells into the osteoblast phenotype
and in BMP-induced heterotopic ossification [9, 10].
These studies have focused on the induction of BMP
expression by T-cell cytokines but have not investigated
whether BMPs have a regulatory effect on T-cell cytokine
function.
In a study published in this volume of Arthritis Research
& Therapy, Varas and co-workers [1] investigated the
modulatory role of BMPs on TNF-α and IL-17 responses
in RA synoviocytes. What emerges from their study is that
pro-inflammatory cytokines and BMP pathways interact.
BMP receptors are expressed on RA synoviocytes, with
ACTRIA/ALK2 and BMPRIA/ALK3 being the most
abundant type I receptors while BMPRII was the most
easily detectable type II receptor. In addition, BMP ligands,
mainly BMP2, and both extracellular and intracellular
BMP inhibitors were also expressed by RA synoviocytes.
As shown by others, expression of BMP ligands was in-
creased by IL-17 and TNF-α, showing an additive effect on
BMP2, 6 and 7 expression. Interestingly, expression of the
intracellular antagonists BAMBI and Smad7 was also en-
hanced by TNF-α/IL-17. However, Smad7 is generally not
considered a genuine BMP signaling inhibitor but a blocker
of TGF-β signaling.
The most appealing finding is that BMP ligands, pro-
duced by autocrine pathways, interfere with the effects of
pro-inflammatory cytokines on RA synoviocytes. Blocking
signaling of endogenously produced BMP ligands by
DMH1, a specific BMP antagonist that inhibits signaling
through ALK1, ALK2, and ALK3, enhanced both the
mRNA and protein expression of IL-8 and granulocyte
macrophage-colony stimulating factor, indicating that
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BMP ligands block the TNF-α/IL-17-induced production
of these cytokines. Moreover, the expression of IL-17-
induced CCL-2 and TNF-α/IL-17-induced matrix metal-
loproteinase (MMP)2 and MMP3 expression was further
enhanced by inhibition of BMP signaling. Vice versa,
addition of exogenous BMP6 inhibited the TNF-α/IL-17-
induced elevated expression of these proteins.
This study shows that the presence of an endogenous
BMP signaling pathway in RA synoviocytes meddles with
the effects of pro-inflammatory cytokines on these cells.
Since it can be anticipated that synoviocytes are exposed
to TNF-α/IL-17 in a joint with active RA, activation of
the BMP pathway might dampen the effects of these
pro-inflammatory cytokines. Furthermore, the authors
hypothesize that BMP signaling could have an anti-
inflammatory role in the control and maintenance of
low levels of pro-inflammatory factors in healthy joints
or the early stage of RA. In this way BMPs have a disease-
controlling action. In contrast, BMPs upregulate their
own antagonists, primarily BAMBI and Smad7. In the
case of Smad7 it can be anticipated that mainly TGF-β
signaling via the Smad2/3-Smad4 route is blocked. Due
to the potent and extensive, chiefly anti-inflammatory,
action of TGF-β, one would expect that BMP-related
induction of Smad7 will limit the anti-inflammatory
action of TGF-β. In this way induction of BMP and
TGF-β inhibitors could contribute to the chronic in-
flammation seen in RA. What is more, the use of
BMPs as an anti-inflammatory route does not seem to
be an attractive option to follow due to the upregula-
tion of BMP and TGF-β signaling inhibitors that will
interfere with the potential anti-inflammatory action of
these ligands.
A limitation of the study by Varas and colleagues is
that synoviocytes between passages 4 and 9 were used.
Although it is known that RA synoviocytes keep their
phenotype in vitro, it cannot be excluded that the role of
BMP signaling is altered during culture on plastic. More-
over, data are not provided that show whether differences
exist between different patient (subgroups) nor what the
effect of medication is. However, due to the late passage in
which cells are studied, the influence of medication can
largely be ruled out.
The major value of this paper is that it shows that BMP
and inflammatory pathways interact. Although these path-
ways, and factors involved, are in many cases studied
separately, Mother Nature is not confined to man-made
boxes. More and more it becomes clear that human
physiology is an holistic system in which the same fac-
tors are used over and over and which shows interfer-
ence on all levels. The paper of Varas and colleagues
clearly shows that inflammation and tissue develop-
ment and maintenance are not separate systems but in-
stead are integrated.
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